Announced Date: 2024-05-16 (May 16, 2024)
Asset Name: JYP0015 (ERAS-0015)
Licensor (Seller): Joyo Pharmatech (China)
Licensee (Buyer): Erasca (US)
.
Asset Modality: Small Molecule
Asset Target: Pan-RAS molecular glue
Potential Indication: oncology diseases
Current Stage: preclinical
.
Scope of Authority:
Erasca will be granted an exclusive license to research, develop and commercialize JYP0015 worldwide (excluding mainland China, Hong Kong, and Macau).
.
Payment Detail:
Joyo will receive
Upfront payment and potential short-term payments of up to USD 20 million,
Development and commercialization milestone payments, up to USD 345 million.
Tiered royalties on net sales.
.
Link:
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise – Erasca
.
Note:
Chinese Name of “Joyo Pharmatech“，嘉越医药
